Skip to main content
Premium Trial:

Request an Annual Quote

SHORT READS: Oct 1, 2002 (rev. 1)


Marligen, a DNA analysis supply company, acquired Clairus Technologies, a biotech specializing in commercializing public- and private-sector IP.


Orchid BioSciences settled its patent lawsuit with Saint Louis University. In the settlement, Orchid acquired full ownership of the disputed patent, which is for SNP-based detection of genetic diseases and sequence variations.


TIGR scientists announced completion of the map for the Streptococcus agalactiae genome, which can cause a life-threatening infection in newborns, pregnant women, and chronically ill people.


Life sciences marketing and consulting firm Krug Consulting Group, run by former-InforMaxer Jane Krug, has opened new offices in Baltimore, Md.


Applied Biosystems and Myriad Proteomics joined in a collaboration to develop new proteomics technologies using ABI’s instruments as the major platform to work from.


SurroMed, based in Mountain View, Calif., was awarded an SBIR from the NCI to support development of the company’s affinity mass tag technologies to be used with mass spec instruments.


Psychiatric Genomics joined forces with the Harvard Brain Tissue Resource Center in an agreement to study schizophrenic and bipolar disorders using gene expression analysis tools.


The Belgian functional genomics firm Devgen announced that it acquired the assets of Elegene, including image acquisition tools and a library of CNS disease models. Devgen expects the technology to further its work with C. elegans.


High Throughput Genomics of Tucson, Ariz., entered into a screening technology supply agreement with drug-discovery firm Celgene.


BioAccelerator, the bioscience incubator that just started up in Fairfax County, Va., claimed as one of its first clients OriGenel, which works in outsourcing bioinformatics R&D projects.


San Diego’s Illumina teamed up with the University of Cambridge to provide SNP genotyping services on samples from a collection at the university’s Institute for Medical Research.


Cellular Genomics opened a new facility for small-molecule drug discovery in Branford, Conn. The facility is 9,000 square feet and will house technologies for high-throughput screening and structure-based drug design.


Agilent Technologies and IBM will work together to build an informatics system to accelerate drug discovery and development for life sciences customers.


Austin, Texas-based Ambion won a $1.6 million SBIR grant from the NIH to continue development of its RNA amplification technology, which could improve DNA microarray results.


Johns Hopkins University researchers announced the discovery of what they call “jumping genes,” which move from one chromosome to another, rearranging the genome. The freshly inserted regions were shown in many cases to delete chunks of DNA wherever they arrived.


Serenex, a Durham, NC-based functional proteomics company, raised more than $15 million in a series B financing round. Intersouth Partners led the funding, which included new investors Lilly Bio- Ventures and Seaflower Ventures as well as previous investor Mediphase Venture Partners.


After doing all it could with short-tandem-repeat analysis, the New York City medical examiner’s office last month began using Orchid’s SNP-IT and SNPstream UHT technologies to try to identify the most degraded remains of victims of the Sept. 11 World Trade Center attack. Orchid’s forensics unit, Cellmark in Dallas, will use secret technology developed at the company’s Princeton headquarters.


The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more